Currently, ACE2 is in clinical trials for the treatment of cardiovascular and metabolic disorders; however, the therapeutic utility of targeting the ACE2/Ang-(1-7) axis for the alleviation of mental health disorders may be only beginning to be realized. This evidence concerns the gene ACE2 and metabolic disease.